| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Victoria M Villaflor | |
| Nicholas P Campbell | |||
| P2860 | cites work | The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 |
| Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity | Q81547151 | ||
| Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy | Q81624678 | ||
| Obesity is an independent risk factor for GERD symptoms and erosive esophagitis | Q81805192 | ||
| Esophageal Cancer Clinical Practice Guidelines | Q82993856 | ||
| Epidemiology of esophageal cancer | Q83572000 | ||
| Preoperative chemotherapy for resectable thoracic esophageal cancer | Q24245213 | ||
| Preoperative radiotherapy for esophageal carcinoma | Q24245676 | ||
| Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline | Q24799989 | ||
| Epidemiology and pathogenesis of esophageal cancer | Q28213313 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data | Q31136509 | ||
| Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma | Q32033905 | ||
| Transhiatal esophagectomy: clinical experience and refinements | Q33736453 | ||
| Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415) | Q34084724 | ||
| A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer | Q34593949 | ||
| Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies | Q34599824 | ||
| Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction | Q34603020 | ||
| Chemoradiotherapy of esophageal cancer | Q34725088 | ||
| Classification of adenocarcinoma of the oesophagogastric junction | Q34755030 | ||
| A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer | Q35143202 | ||
| Section II: pathology and pathologic staging of esophageal cancer | Q35168031 | ||
| Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis | Q35803550 | ||
| Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy | Q35805114 | ||
| Vascular endothelial growth factor in esophageal cancer | Q35849980 | ||
| Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists | Q35880879 | ||
| Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis | Q36021466 | ||
| Novel targeted therapies in the treatment of gastric and esophageal cancer | Q36175741 | ||
| Targeted therapies for esophageal cancer | Q36263992 | ||
| Are squamous and adenocarcinomas of the esophagus the same disease? | Q36690742 | ||
| Prognosis of early esophageal cancer. Comparison between adeno- and squamous cell carcinoma | Q71067123 | ||
| A comparison of multimodal therapy and surgery for esophageal adenocarcinoma | Q71164736 | ||
| [Radical nature and life expectancy in the surgical treatment of esophageal and cardial carcinoma] | Q71296414 | ||
| Preoperative radiotherapy for carcinoma of the esophagus | Q71572381 | ||
| Induction chemotherapy in the treatment of patients with carcinoma of the esophagus | Q71633210 | ||
| Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification | Q72078811 | ||
| A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus | Q72313681 | ||
| A prospective study of combined therapy in esophageal cancer | Q72802585 | ||
| Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus | Q73502951 | ||
| Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial | Q73624732 | ||
| Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials | Q73756660 | ||
| Demographic variations in the rising incidence of esophageal adenocarcinoma in white males | Q74373937 | ||
| Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus | Q74593805 | ||
| Radical radiotherapy for carcinoma of the oesophagus: an effective alternative to surgery | Q77358004 | ||
| [A randomized clinical study of preoperative chemotherapy for esophageal carcinoma] | Q77466931 | ||
| INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy | Q77706014 | ||
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer | Q77738544 | ||
| Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus | Q79258236 | ||
| Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome | Q79522451 | ||
| Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? | Q79847207 | ||
| Combined modality therapy of esophageal cancer: changes in the standard of care? | Q80200233 | ||
| Management of gastroesophageal tumors | Q36734492 | ||
| Hypoxic radiosensitization: adored and ignored | Q36935082 | ||
| Epidermal growth factor receptor-directed therapy in esophageal cancer | Q37162929 | ||
| Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). | Q37401491 | ||
| Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. | Q37449181 | ||
| Emerging drugs for esophageal cancer | Q37488281 | ||
| Esophageal cancer: is esophagectomy necessary? | Q38788636 | ||
| Oesophageal squamous cell carcinoma: II. A critical review of radiotherapy | Q40098647 | ||
| Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma | Q40271053 | ||
| Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. | Q40475456 | ||
| Surveillance for Barrett's oesophagus. The conundrum of Barrett's oesophagus is changing | Q42772013 | ||
| Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research | Q43436684 | ||
| Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. | Q43453588 | ||
| Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group | Q43463195 | ||
| Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). | Q43604675 | ||
| Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy v | Q43629491 | ||
| Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer | Q43956924 | ||
| Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial | Q44017893 | ||
| Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. | Q44022873 | ||
| Smoking, type of alcoholic beverage and squamous-cell oesophageal cancer in northern Italy | Q44605057 | ||
| Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial | Q44639718 | ||
| Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. | Q44691624 | ||
| A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma | Q44902232 | ||
| Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan | Q45083959 | ||
| Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer | Q45192913 | ||
| Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. | Q45956359 | ||
| Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis | Q46331162 | ||
| Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. | Q46675470 | ||
| Predictors of operative death after oesophagectomy for carcinoma | Q47787264 | ||
| Esophageal carcinoma: prognostic differences between squamous cell carcinoma and adenocarcinoma. | Q47879656 | ||
| A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. | Q50939021 | ||
| Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences. | Q51694804 | ||
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. | Q51776237 | ||
| Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients. | Q53395748 | ||
| Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: A prospective randomized study | Q53644293 | ||
| Esophageal Cancer | Q56209683 | ||
| A Prospective Study of Tobacco, Alcohol, and the Risk of Esophageal and Gastric Cancer Subtypes | Q57481108 | ||
| Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women | Q58024083 | ||
| Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma | Q58204833 | ||
| Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World | Q58484706 | ||
| Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group | Q67526968 | ||
| Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus | Q68122887 | ||
| Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus | Q69033494 | ||
| The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. | Q69254547 | ||
| Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients | Q69487537 | ||
| Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study | Q70554151 | ||
| Is surgery necessary with multimodality treatment of oesophageal cancer | Q70930113 | ||
| 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research | Q70992002 | ||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | esophageal cancer | Q372701 |
| P304 | page(s) | 3793-3803 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Neoadjuvant treatment of esophageal cancer | |
| P478 | volume | 16 |
| Q35218636 | A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage |
| Q35130286 | An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer |
| Q47133025 | Composite metrics in response assessment-new hope in oesophageal cancer? |
| Q60948062 | EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway |
| Q41613887 | Effects of neoadjuvant chemotherapy combined with radiotherapy in patients with advanced esophageal carcinoma |
| Q47099330 | Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation? |
| Q35870351 | Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma |
| Q38919838 | Esophageal stent fixation with endoscopic suturing device improves clinical outcomes and reduces complications in patients with locally advanced esophageal cancer prior to neoadjuvant therapy: a large multicenter experience |
| Q36848814 | Experience with oesophageal cancer: a ten-year single centre study reflecting daily practice |
| Q42534789 | Gastroesophageal reflux disease: From heartburn to cancer |
| Q43608573 | Influence of treatment modality in outcomes for different stages of resectable esophageal adenocarcinomas |
| Q27311384 | Inhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasis |
| Q37629689 | Is endoscopic ultrasound examination necessary in the management of esophageal cancer? |
| Q36027111 | Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro |
| Q40378167 | Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer |
| Q37091635 | Methylation of TFPI-2 is an early event of esophageal carcinogenesis |
| Q37988359 | MicroRNA and its roles in esophageal cancer. |
| Q27010074 | Minimally invasive surgery for esophageal cancer: review of the literature and institutional experience |
| Q38067386 | Multidisciplinary approach for patients with esophageal cancer |
| Q87102005 | Multimodality management of esophageal cancer |
| Q35189373 | Myricetin enhance chemosensitivity of 5-fluorouracil on esophageal carcinoma in vitro and in vivo |
| Q35190260 | Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials |
| Q48909742 | Prognostic factors for post-recurrence survival in esophageal squamous cell carcinoma patients with recurrence after resection |
| Q36376503 | Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer |
| Q52984885 | Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery. |
| Q37812294 | The value of epigenetic markers in esophageal cancer |
| Q51067056 | Treatment of clinical T2N0M0 esophageal cancer. |
Search more.